Ajax Set To ‘Attack JAK’ In Myelofibrosis With $95m In Series C Cash

Will Advance Myeloproliferative Neoplasm Pipeline

 
• By Mandy Jackson
  
Venture capital. Investor capital. 3d illustration
Ajax previously raised $48m in series A and B rounds • Source: Shutterstock

More from Financing

More from Business